中国药理学通报2026，Vol.42Issue(2)：296-304,9.DOI:10.12360/CPB202505066
丹酚酸B对Hepa1-6细胞及其小鼠荷瘤抑制作用及机制
The inhibitory effect of salvianolic acid B on Hepa1-6 cells and tumor-bearing mice
摘要
Abstract
Aim To investigate the inhibitory effect of salvianolicacid B(Sal B)on mouse hepatocellular car-cinoma cells(Hepa1-6)and to explore its role through the TGF-β1/Smad2 signaling pathway.Methods Hepa1-6 cells were divided into the control group,TGF-β1 stimulation group,and TGF-β1+Sal B group.Cell proliferation and migration ability were assessed.PSmad2C,pSmad2L expression levels,pSmad2C,pSmad2L and Smad2 protein changes were detected using cellular immunofluorescence.Tumorigenic mice were randomly divided into the model group,Sal B(7.5 mg·kg-1·d-1)group,Sal B(15 mg·kg-1·d-1)group,Sal B(30 mg·kg-1·d-1)group,and colchicine group(0.1 mg·kg-1·d-1),with 8 mice in each group.Body weight,tumor volume changes,tumor histopa-thology,pSmad2C,pSmad2L protein changes were all detected.Results Sal B effectively inhibited the TGF-β1induced proliferation and migration of Hepa1-6 cells,concomitantly reducing the protein expression levels of pSmad2C and pSmad2L.In vivo,Sal B po-tently suppressed tumor growth in a xenograft model in a dose-dependent manner.Histopathological(HE)staining and Western blot analysis further confirmed that Sal B treatment inhibited tumor growth and down-regulated the protein expression of pSmad2C and pSmad2L in tumor tissues.Conclusions Sal B exhib-its a significant inhibitory effect on the growth of Hepa1-6 cells stimulated by TGF-β1,and this mecha-nism may be closely associated with the activation of the TGF-β1/Smad2 signaling pathway.Furthermore,the inhibitory effect of Sal B on TGF-β1-induced tumor growth in vivo is likely mediated through the activation of the TGF-β1/Smad2 signaling pathway.关键词
丹酚酸B/肝癌/TGFβ1/Smad2信号通路/Hepa1-6/细胞增殖与迁移/荷瘤Key words
salvianolic acid B/hepatocarcinoma/TGFβ1/Smad2 signaling pathway/Hepa1-6/Cell pro-liferation and migration/tumor-bearing分类
医药卫生引用本文复制引用
刘文博,孙良捷,邓洁,贾心璐,杨雁..丹酚酸B对Hepa1-6细胞及其小鼠荷瘤抑制作用及机制[J].中国药理学通报,2026,42(2):296-304,9.基金项目
国家自然科学基金资助项目(No 82374084) （No 82374084）
国家级大学生创新训练计划项目(No 202310366026) （No 202310366026）
临床医学"5+3"一体化专业(含儿科学方向)"早期接触科研"训练计划项目(No 2022-ZQKY-175,2023-ZQKY-144) （含儿科学方向）
